Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys

Peter Abbink; Rafael A. Larocca; Rafael A. De La Barrera; Christine A. Bricault; Edward T. Moseley; Michael Boyd; Marinela Kirilova; Zhenfeng Li; David Ng'ang'a; Ovini Nanayakkara; Ramya Nityanandam; Noe B. Mercado; Erica N. Borducchi; Arshi Agarwal; Amanda L. Brinkman; Crystal Cabral; Abishek Chandrashekar; Patricia B. Giglio; David Jetton; Jessica Jimenez; Benjamin C. Lee; Shanell Mojta; Katherine Molloy; Mayuri Shetty; George H. Neubauer; Kathryn E. Stephenson; Jean Pierre S. Peron; Paolo M.A. De Zanotto; Johnathan Misamore; Brad Finneyfrock; Mark G. Lewis; Galit Alter; Kayvon Modjarrad; Richard G. Jarman; Kenneth H. Eckels; Nelson L. Michael; Stephen J. Thomas; Dan H. Barouch

doi:10.1126/science.aah6157

Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys

Peter Abbink, Rafael A. Larocca, Rafael A. De La Barrera, Christine A. Bricault, Edward T. Moseley, Michael Boyd, Marinela Kirilova, Zhenfeng Li, David Ng'ang'a, Ovini Nanayakkara, Ramya Nityanandam, Noe B. Mercado, Erica N. Borducchi, Arshi Agarwal, Amanda L. Brinkman, Crystal Cabral, Abishek Chandrashekar, Patricia B. Giglio, David Jetton, Jessica JimenezBenjamin C. Lee, Shanell Mojta, Katherine Molloy, Mayuri Shetty, George H. Neubauer, Kathryn E. Stephenson, Jean Pierre S. Peron, Paolo M.A. De Zanotto, Johnathan Misamore, Brad Finneyfrock, Mark G. Lewis, Galit Alter, Kayvon Modjarrad, Richard G. Jarman, Kenneth H. Eckels, Nelson L. Michael, Stephen J. Thomas, Dan H. Barouch^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

425 Scopus citations

Abstract

Zika virus (ZIKV) is responsible for a major ongoing epidemic in the Americas and has been causally associated with fetalmicrocephaly. The development of a safe and effective ZIKV vaccine is therefore an urgent global health priority. Here we demonstrate that three different vaccine platforms protect against ZIKVchallenge in rhesus monkeys. A purified inactivated virus vaccine induced ZIKV-specific neutralizing antibodies and completely protected monkeys against ZIKV strains from both Brazil and Puerto Rico. Purified immunoglobulin from vaccinated monkeys also conferred passive protection in adoptive transfer studies. A plasmid DNAvaccine and a single-shot recombinant rhesus adenovirus serotype 52 vector vaccine, both expressing ZIKV premembrane and envelope, also elicited neutralizing antibodies and completely protected monkeys against ZIKVchallenge. These data support the rapid clinical development of ZIKV vaccines for humans.

Original language	English
Pages (from-to)	1129-1132
Number of pages	4
Journal	Science
Volume	353
Issue number	6304
DOIs	https://doi.org/10.1126/science.aah6157
State	Published - 9 Sep 2016
Externally published	Yes

Access to Document

10.1126/science.aah6157

Cite this

Abbink, P., Larocca, R. A., De La Barrera, R. A., Bricault, C. A., Moseley, E. T., Boyd, M., Kirilova, M., Li, Z., Ng'ang'a, D., Nanayakkara, O., Nityanandam, R., Mercado, N. B., Borducchi, E. N., Agarwal, A., Brinkman, A. L., Cabral, C., Chandrashekar, A., Giglio, P. B., Jetton, D., ... Barouch, D. H. (2016). Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science, 353(6304), 1129-1132. https://doi.org/10.1126/science.aah6157

@article{050974e06e2a4107ab92b857795b831f,

title = "Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys",

abstract = "Zika virus (ZIKV) is responsible for a major ongoing epidemic in the Americas and has been causally associated with fetalmicrocephaly. The development of a safe and effective ZIKV vaccine is therefore an urgent global health priority. Here we demonstrate that three different vaccine platforms protect against ZIKVchallenge in rhesus monkeys. A purified inactivated virus vaccine induced ZIKV-specific neutralizing antibodies and completely protected monkeys against ZIKV strains from both Brazil and Puerto Rico. Purified immunoglobulin from vaccinated monkeys also conferred passive protection in adoptive transfer studies. A plasmid DNAvaccine and a single-shot recombinant rhesus adenovirus serotype 52 vector vaccine, both expressing ZIKV premembrane and envelope, also elicited neutralizing antibodies and completely protected monkeys against ZIKVchallenge. These data support the rapid clinical development of ZIKV vaccines for humans.",

author = "Peter Abbink and Larocca, {Rafael A.} and {De La Barrera}, {Rafael A.} and Bricault, {Christine A.} and Moseley, {Edward T.} and Michael Boyd and Marinela Kirilova and Zhenfeng Li and David Ng'ang'a and Ovini Nanayakkara and Ramya Nityanandam and Mercado, {Noe B.} and Borducchi, {Erica N.} and Arshi Agarwal and Brinkman, {Amanda L.} and Crystal Cabral and Abishek Chandrashekar and Giglio, {Patricia B.} and David Jetton and Jessica Jimenez and Lee, {Benjamin C.} and Shanell Mojta and Katherine Molloy and Mayuri Shetty and Neubauer, {George H.} and Stephenson, {Kathryn E.} and Peron, {Jean Pierre S.} and {De Zanotto}, {Paolo M.A.} and Johnathan Misamore and Brad Finneyfrock and Lewis, {Mark G.} and Galit Alter and Kayvon Modjarrad and Jarman, {Richard G.} and Eckels, {Kenneth H.} and Michael, {Nelson L.} and Thomas, {Stephen J.} and Barouch, {Dan H.}",

year = "2016",

month = sep,

day = "9",

doi = "10.1126/science.aah6157",

language = "English",

volume = "353",

pages = "1129--1132",

journal = "Science",

issn = "0036-8075",

number = "6304",

}

Abbink, P, Larocca, RA, De La Barrera, RA, Bricault, CA, Moseley, ET, Boyd, M, Kirilova, M, Li, Z, Ng'ang'a, D, Nanayakkara, O, Nityanandam, R, Mercado, NB, Borducchi, EN, Agarwal, A, Brinkman, AL, Cabral, C, Chandrashekar, A, Giglio, PB, Jetton, D, Jimenez, J, Lee, BC, Mojta, S, Molloy, K, Shetty, M, Neubauer, GH, Stephenson, KE, Peron, JPS, De Zanotto, PMA, Misamore, J, Finneyfrock, B, Lewis, MG, Alter, G, Modjarrad, K, Jarman, RG, Eckels, KH, Michael, NL, Thomas, SJ & Barouch, DH 2016, 'Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys', Science, vol. 353, no. 6304, pp. 1129-1132. https://doi.org/10.1126/science.aah6157

TY - JOUR

T1 - Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys

AU - Abbink, Peter

AU - Larocca, Rafael A.

AU - De La Barrera, Rafael A.

AU - Bricault, Christine A.

AU - Moseley, Edward T.

AU - Boyd, Michael

AU - Kirilova, Marinela

AU - Li, Zhenfeng

AU - Ng'ang'a, David

AU - Nanayakkara, Ovini

AU - Nityanandam, Ramya

AU - Mercado, Noe B.

AU - Borducchi, Erica N.

AU - Agarwal, Arshi

AU - Brinkman, Amanda L.

AU - Cabral, Crystal

AU - Chandrashekar, Abishek

AU - Giglio, Patricia B.

AU - Jetton, David

AU - Jimenez, Jessica

AU - Lee, Benjamin C.

AU - Mojta, Shanell

AU - Molloy, Katherine

AU - Shetty, Mayuri

AU - Neubauer, George H.

AU - Stephenson, Kathryn E.

AU - Peron, Jean Pierre S.

AU - De Zanotto, Paolo M.A.

AU - Misamore, Johnathan

AU - Finneyfrock, Brad

AU - Lewis, Mark G.

AU - Alter, Galit

AU - Modjarrad, Kayvon

AU - Jarman, Richard G.

AU - Eckels, Kenneth H.

AU - Michael, Nelson L.

AU - Thomas, Stephen J.

AU - Barouch, Dan H.

PY - 2016/9/9

Y1 - 2016/9/9

N2 - Zika virus (ZIKV) is responsible for a major ongoing epidemic in the Americas and has been causally associated with fetalmicrocephaly. The development of a safe and effective ZIKV vaccine is therefore an urgent global health priority. Here we demonstrate that three different vaccine platforms protect against ZIKVchallenge in rhesus monkeys. A purified inactivated virus vaccine induced ZIKV-specific neutralizing antibodies and completely protected monkeys against ZIKV strains from both Brazil and Puerto Rico. Purified immunoglobulin from vaccinated monkeys also conferred passive protection in adoptive transfer studies. A plasmid DNAvaccine and a single-shot recombinant rhesus adenovirus serotype 52 vector vaccine, both expressing ZIKV premembrane and envelope, also elicited neutralizing antibodies and completely protected monkeys against ZIKVchallenge. These data support the rapid clinical development of ZIKV vaccines for humans.

AB - Zika virus (ZIKV) is responsible for a major ongoing epidemic in the Americas and has been causally associated with fetalmicrocephaly. The development of a safe and effective ZIKV vaccine is therefore an urgent global health priority. Here we demonstrate that three different vaccine platforms protect against ZIKVchallenge in rhesus monkeys. A purified inactivated virus vaccine induced ZIKV-specific neutralizing antibodies and completely protected monkeys against ZIKV strains from both Brazil and Puerto Rico. Purified immunoglobulin from vaccinated monkeys also conferred passive protection in adoptive transfer studies. A plasmid DNAvaccine and a single-shot recombinant rhesus adenovirus serotype 52 vector vaccine, both expressing ZIKV premembrane and envelope, also elicited neutralizing antibodies and completely protected monkeys against ZIKVchallenge. These data support the rapid clinical development of ZIKV vaccines for humans.

UR - http://www.scopus.com/inward/record.url?scp=84981501423&partnerID=8YFLogxK

U2 - 10.1126/science.aah6157

DO - 10.1126/science.aah6157

M3 - Article

C2 - 27492477

AN - SCOPUS:84981501423

SN - 0036-8075

VL - 353

SP - 1129

EP - 1132

JO - Science

JF - Science

IS - 6304

ER -

Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys

Abstract

Access to Document

Fingerprint

Cite this